Affiliation:
1. North Staffordshire Rehabilitation Centre, Haywood Hospital, Stoke-on-Trent ST6 7AG, UK
2. Ipsen, Slough SL1 3XE, UK
3. Ipsen, 92100 Boulogne-Billancourt, France
Abstract
Service model changes at the North Staffordshire Rehabilitation Centre (UK) included switching spasticity treatment from onabotulinumtoxinA (onaBoNT-A) to abobotulinumtoxinA (aboBoNT-A). This noninterventional, retrospective, longitudinal study (NCT04396704) describes the clinical and economic outcomes in toxin-naive adults with spasticity who received onaBoNT-A (Cohort 1; 2015–2017) or aboBoNT-A (Cohort 2; 2017–2019). Outcomes included Goal Attainment Scale T (GAS-T) score, treatment satisfaction, quality of life (QoL; EQ-5D visual analog scale [VAS] score), and treatment costs. Adverse events were recorded for Cohort 2. Cohort 1 included 60 patients (mean [standard deviation] dose, 206.0 [98.8] U); Cohort 2 included 54 patients (753.7 [457.3] U). Mean (95% confidence interval) GAS-T scores for Cohorts 1 and 2 were 43.1 (39.3–46.9) and 47.8 (43.7–51.9) at Week 6, and 43.2 and 44.3 at Week 12, respectively. In both cohorts most patients were satisfied with treatment. At Week 12, QoL had not changed in Cohort 1 but had improved in Cohort 2 (EQ-5D VAS, −5). Mean estimated per-patient costs (in 2021) for Cohorts 1 and 2 were £315.56 and £249.25, respectively, at Week 6, and £343.20 and £273.21, respectively, at Week 12. Fifteen non–treatment-related serious adverse events and two deaths were recorded. These data may warrant a larger prospective study powered to compare outcomes of aboBoNT-A and onaBoNT-A.
Subject
Health, Toxicology and Mutagenesis,Toxicology
Reference32 articles.
1. Spasticity: Clinical perceptions, neurological realities and meaningful measurement;Pandyan;Disabil. Rehabil.,2005
2. Perspective of an an international online patient and caregiver community on the burden of spasticity and impact of botulinum neurotoxin therapy: Survey study;Patel;JMIR Public Health Surveill.,2020
3. Royal College of Physicians, The British Society Of Rehabilitation Medicine, The Chartered Society of Physiotherapy, and Association of Chartered Physiotherapists in Neurology and the Royal College of Occupational Therapists (2018). Spasticity in Adults: Management Using Botulinum Toxin National Guidelines, Royal College of Physician. [2nd ed.].
4. Spasticity treatment with botulinum toxin;Ward;Turk. J. Phys. Med. Rehab.,2007
5. Improving the management of post-stroke spasticity: Time for action;Christofi;J. Rehabil. Med. Clin. Commun.,2018